DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT04615910

Ver-A-image

UnknownPhase 2

A GLP-1 Receptor PET Imaging Substudy Within the VER-A-T1D Trial Investigating the Effects on Beta Cell Mass

Asset

Exenatide

GLP-1 agonist

Listed sites

2

Recruiting sites

2

Enrollment

30

estimated

Study population

Type 1 diabetes

Key I/E criterion

—

Primary endpoint

•Pancreatic 68Ga-exendin uptake

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT04615910
Org study ID20201013

Timeline

Milestones

Study first posted2020-11-04actual
Study start2021-07-01actual
Last update posted2023-12-08actual
Primary completion2025-04-01estimated
Study completion2025-07-01estimated

Assets

Investigational agents

Exenatide

Study populations

Who this study enrolls

Type 1 diabetes

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•• Have given written informed consent
•• Age ≥18 and <45 at consent
•• Must have a diagnosis of T1D of within 6 weeks duration at screening (date of the first insulin
•injection)
•• Must have at least one or more diabetes-related autoantibodies present at screening
•• Must have random C-peptide levels ≥200 pmol/L measured at screening
•• Be willing to comply with intensive diabetes management

Exclusion criteria

•Treatment with synthetic Exendin (Exenatide, Byetta®) or Dipeptidyl-Peptidase IV inhibitors (to exclude interferences with imaging, specifically mentioned although in principle part of exclusion criteria of VER-A-T1D)
•Renal disease defined as MDRD <40 ml/min/1.73 m2
•Pregnancy or the wish to become pregnant within 2 months after the second PET/CT scan.

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Other (unclassified)

3 endpoints
Primary/protocol endpoint/low confidence

Pancreatic 68Ga-exendin uptake

Time frame:Change from time of inclusion to 12 months into treatment

change from baseline, descriptive

Secondary/protocol endpoint/low confidence

Correlation of 68Ga-exendin uptake and C-peptide

Time frame:12 months into treatment

descriptive

Secondary/protocol endpoint/low confidence

relative 68Ga-exendin uptake

Time frame:12 months into treatment

percent change from baseline, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.